Latest / Bloomberg Law / Drug Makers Sued for Fueling Opioid Epidemic (Audio)
Transcript
- 0:00Speaker 1: The costs of the opioid epidemic are mounting for states
- 0:03Speaker 1: and local governments. They're paying more for both treatment efforts
- 0:06Speaker 1: and law enforcement, and they are increasingly trying to recoup
- 0:10Speaker 1: that money through lawsuits. More than twenty five states, counties,
- 0:13Speaker 1: and cities are now pressing cases against drug makers, distributors,
- 0:17Speaker 1: and pharmacy chains. It's an approach that hearkens back to
- 0:21Speaker 1: the nineteen nineties and the state lawsuits that eventually led
- 0:24Speaker 1: to a two hundred billion dollar settlement with America's cigarette makers.
- 0:28Speaker 1: Is the opioid industry going to follow the same legal path?
- 0:33Speaker 1: We're gonna ask our two guests, Richard Austiness, he's a
- 0:35Speaker 1: professor at the University of Kentucky School of Law, and
- 0:38Speaker 1: Jodie Abragan, a partner at KD Walader and former chief
- 0:42Speaker 1: of staff of the Drug Enforcement Administration. Welcome to you both.
- 0:46Speaker 1: Thanks for joining us. Richard, Before we get into the
- 0:50Speaker 1: prospects for success of these lawsuits, can you just give
- 0:54Speaker 1: us a rough overview of the kinds of allegations we're
- 0:57Speaker 1: talking about. What what sorts of things have drug makers
- 0:59Speaker 1: and other panis allegedly done wrong? Well, it's um the
- 1:05Speaker 1: allegations are that they marketed their products in such a
- 1:09Speaker 1: way that uh it encouraged addiction or led to addiction
- 1:14Speaker 1: on the part of many of the users. UH. They're
- 1:17Speaker 1: actually a number of things that they're accused of doing.
- 1:20Speaker 1: First of all, misrepresenting the addictive qualities to the f
- 1:24Speaker 1: d A and later to physicians in order to encourage
- 1:28Speaker 1: them to UH prescribe these drugs when they weren't necessary.
- 1:33Speaker 1: And then secondly, their marketing practices UH were such that
- 1:40Speaker 1: they allowed their distributors to send very large amounts of
- 1:46Speaker 1: opioids to uh Appalachi in particular, but elsewhere the United States,
- 1:51Speaker 1: far more than would be reasonably necessary, UH, either knowing
- 1:57Speaker 1: or suspecting that they were going to be issues sent
- 2:02Speaker 1: into the black market, and so forth. And Jody, which
- 2:07Speaker 1: uh sort of sector is most vulnerable here? Are we
- 2:11Speaker 1: mostly talking about the manufacturers of these drugs? Are we
- 2:15Speaker 1: talking about the distributors, we're talking about the pharmacy chains
- 2:20Speaker 1: or or they all sort of equally at risk here.
- 2:23Speaker 1: And I think that certainly the lawsuits started with manufacturers,
- 2:29Speaker 1: they moved to distributors. UH. There was some success in
- 2:32Speaker 1: West Virginia against the Big three distributors, but the lawsuits
- 2:36Speaker 1: of late have focused on the manufacturers and focused on
- 2:40Speaker 1: the marketing practices as as Richard just described. However, I
- 2:46Speaker 1: think that all aspects of the supply chain are at risk. Um.
- 2:51Speaker 1: There is the significant law enforcement effort with with respect
- 2:56Speaker 1: to pharmacies, pharmacists and physicians as well, but there are
- 3:00Speaker 1: just so many of them that I think that law
- 3:03Speaker 1: enforcement and plaintiffs attorneys have decided that the best, uh,
- 3:09Speaker 1: the best chance for having an impact is on the
- 3:12Speaker 1: manufacturers and distributors. Richard, There's been an awful lot of
- 3:18Speaker 1: talk comparing the situation to what happened with the tobacco
- 3:22Speaker 1: industry back in the nineties. To what extent do you
- 3:27Speaker 1: think that as an apt parallel When this story first broke,
- 3:33Speaker 1: I felt it was closer to the situation that occurred
- 3:36Speaker 1: with firearms that as far as the theories of liability
- 3:40Speaker 1: were used. But I think what's what's starting to happen
- 3:43Speaker 1: now is is this Oklahoma land rush syndrome, and that
- 3:48Speaker 1: does resemble the tobacco cases. I think, UM, that is
- 3:52Speaker 1: to say, uh, large numbers of plaintiffs are bringing suit,
- 3:57Speaker 1: uh not so much expecting to in but to force
- 4:02Speaker 1: or encourage a settlement, and I think in that respect
- 4:05Speaker 1: it strongly resembles the what happened in with the tobacco
- 4:09Speaker 1: cases twenty years ago. Jody, what's your take on that?
- 4:13Speaker 1: Do you agree that these suits are primarily or at
- 4:19Speaker 1: least to a large degree, focused on winning a settlement
- 4:22Speaker 1: as opposed to winning a verdict? You know, I think
- 4:27Speaker 1: I think it's an interesting question. Certainly, uh so many
- 4:31Speaker 1: communities have legitimate losses. The expenses of caring for addicted
- 4:38Speaker 1: populations are tremendous, so the losses are real. UM. I
- 4:43Speaker 1: am not sure whether UM plaintiffs are seeking to affect
- 4:49Speaker 1: conduct or get money. I suspect it's it really is
- 4:53Speaker 1: a little bit of both. And if I could just
- 4:56Speaker 1: UM comment also on your on your question about UM
- 5:00Speaker 1: how reminiscent this is of tobacco litigation. I think a
- 5:04Speaker 1: critical distinction is that the manufacturers and distributors and indeed
- 5:08Speaker 1: pharmacists UM and and doctors who who are being sued
- 5:13Speaker 1: are for the very large part in the business of healthcare.
- 5:17Speaker 1: They exist to make people better. They make medicine, they
- 5:20Speaker 1: distribute medicine, and that really is a critical distinction. Although
- 5:25Speaker 1: again I agree with Richard that that the parallels are
- 5:29Speaker 1: striking at first glance, it is. Uh. Well, Richard, let
- 5:34Speaker 1: me just ask you to sort of pick up on that.
- 5:36Speaker 1: Is UM trying to decide as Jody was talking there,
- 5:40Speaker 1: if if your comparison to the gun industry is uh
- 5:45Speaker 1: is closer or not? Are are we? Um? You know,
- 5:48Speaker 1: the gun industry is an industry that I think, you know,
- 5:51Speaker 1: maybe it's not healthcare. They're not trying to help people
- 5:53Speaker 1: in that way, but it is at least a legal
- 5:57Speaker 1: product that generally isn't regulated. So, uh, where does where
- 6:03Speaker 1: do opioid sort of fit in that? Maybe expand on
- 6:06Speaker 1: what you're saying about it being more like the guns
- 6:08Speaker 1: than than like tobacco. Well, I was thinking that the
- 6:12Speaker 1: liability theories they were using, particularly the public nuisance theory, UH,
- 6:17Speaker 1: fit the gun cases a bit more than the tobacco cases.
- 6:21Speaker 1: That theory is the assumes that the social costs, the
- 6:27Speaker 1: healthcare costs, the law enforcement costs are that these communities
- 6:31Speaker 1: have incurred are directly attributed to the marketing practices of
- 6:36Speaker 1: the of the particular industry. I don't think that was
- 6:41Speaker 1: um a common theory with the tobacco cases, but it
- 6:46Speaker 1: certainly fits the opioid cases. We're talking about the opioid epidemic,
- 6:50Speaker 1: and in particular the lawsuits by more than twenty five states, counties,
- 6:54Speaker 1: and cities trying to recoup potentially billions of dollars they've
- 6:58Speaker 1: spent on treatment efforts, law enforcement, and other expenses. Are
- 7:02Speaker 1: Our guests are Richard Austiness, who's a professor at the
- 7:04Speaker 1: University of Kentucky School of Law, and Jodie Evergun, who's
- 7:08Speaker 1: a partner at CAD Walder and a former official at
- 7:11Speaker 1: the Drug Enforcement Administration UM. The one defense I've seen
- 7:17Speaker 1: described for companies in these cases is essentially the UH
- 7:21Speaker 1: the f d A approved it defense. UH. These are
- 7:25Speaker 1: products that were approved by the FDA. The warnings were
- 7:27Speaker 1: approved by by the f d A. How much does
- 7:31Speaker 1: that shield UH drug manufacturers and others UH in these lawsuits. Well,
- 7:37Speaker 1: it's it's certainly an argument they can make. I don't
- 7:40Speaker 1: don't think it would be an absolute defense, but UH,
- 7:44Speaker 1: it certainly allows the drug companies to say we didn't
- 7:46Speaker 1: do anything wrong at least in so far as the
- 7:51Speaker 1: warnings are concerned. Now, that really doesn't go to their
- 7:53Speaker 1: marketing practices, which I think is involves a separate issue.
- 7:57Speaker 1: But um, Yeah, unlike the tobacco cases, where cigarettes were
- 8:03Speaker 1: of course not highly regulated, UH, opioids in particular are
- 8:08Speaker 1: and the f d A, as you say, proved the
- 8:11Speaker 1: warnings approved the UM the licensing of the drug, and
- 8:19Speaker 1: that odd account for something at least it's an argument
- 8:22Speaker 1: that the drug companies can raise. Well, Richard, they will
- 8:26Speaker 1: be raising that question that that defense, of course. But
- 8:31Speaker 1: if you look at this from the perspective of, you know,
- 8:34Speaker 1: what should they have done according to the plaintiffs, and
- 8:38Speaker 1: potentially might they be liable for it? What kind of
- 8:40Speaker 1: actions should these drug companies, the manufacturers and distributors have
- 8:45Speaker 1: taken to avoid the problem here. Well, certainly they should
- 8:49Speaker 1: have monitored the UH sales by their distributors. In in
- 8:56Speaker 1: at least a number of cases, pharmacies and relatively low
- 9:01Speaker 1: populated areas were purchasing huge amounts of opioids. UM. That
- 9:07Speaker 1: and in that sense it resembles the gun cases. Uh.
- 9:10Speaker 1: They should have smelled a wrap. I should have realized
- 9:12Speaker 1: something is not right here. UH. And the Everett case,
- 9:16Speaker 1: which was reported in the media recently, is a good
- 9:20Speaker 1: example of that that. Um, they didn't do anything. They
- 9:26Speaker 1: didn't inform the FDA. They their own monitoring revealed that
- 9:30Speaker 1: there was something very wrong, but they didn't do anything
- 9:35Speaker 1: about it. And of course the planists will say they
- 9:38Speaker 1: didn't do anything about it because they were making money
- 9:40Speaker 1: hand over fist selling opioids and had no incentive to
- 9:44Speaker 1: do anything about it. But it's certainly UM could get
- 9:47Speaker 1: them into a lot of trouble. Jody Avergant is back
- 9:50Speaker 1: with us. Jody, I want to ask you you're you're
- 9:53Speaker 1: in private practice, and I want to know what your
- 9:55Speaker 1: sense is about about the plane off spar In. In
- 9:59Speaker 1: these cases the is lawsuits back with tobacco, and now
- 10:03Speaker 1: go forward when state attorney's general ally themselves with law firms,
- 10:08Speaker 1: and I'm wondering how much enthusiasm you are detecting from
- 10:13Speaker 1: the plaintiff side in these cases. Are our law firms
- 10:17Speaker 1: jumping aboard these these suits. I think that a perfect
- 10:22Speaker 1: example of how enthusiastic the bar is is the fact
- 10:25Speaker 1: that Delaware is able to put out a request for proposal,
- 10:28Speaker 1: meaning that they're they're searching far and wide for law
- 10:32Speaker 1: firms to do this UM, and there seems to be
- 10:35Speaker 1: no dearth of of firms willing to jump on this bandwagon.
- 10:41Speaker 1: I'm just not sure that it is the right way
- 10:43Speaker 1: to address the opioid crisis. Uh. Certainly, UM. I think
- 10:48Speaker 1: that plane of c dollar signs and they realize that
- 10:51Speaker 1: settlements are likely in these cases. UM. The money, frankly
- 10:55Speaker 1: is just better spent uh for both the companies and
- 11:00Speaker 1: counties and states to improve prescription drug monitoring programs, to
- 11:04Speaker 1: put money into treatment um and and really focus on
- 11:09Speaker 1: addressing the problem. UM. I respectfully disagree with Richard that
- 11:15Speaker 1: that manufacturers and distributors have been ignoring the problem for ages.
- 11:19Speaker 1: I think that steps have been taken by most d
- 11:23Speaker 1: e A registaurants to address the problem. Um Uh. Perhaps
- 11:28Speaker 1: um not as quickly as the problem was developing, which
- 11:32Speaker 1: is why there is an opioid crisis now. But UM
- 11:37Speaker 1: I think that it is um too simplistic to just
- 11:41Speaker 1: lay it at the feet of manufacturers and distributors, because
- 11:45Speaker 1: there are significant intervening circumstances here, such as bad doctors
- 11:50Speaker 1: who prescribe, or doctors who legitimately believe that their patients
- 11:53Speaker 1: are in pain, or drug addicts who who really require
- 11:58Speaker 1: medicine to function, um and and might not have been
- 12:02Speaker 1: illegitimately getting the products. And then of course there's a
- 12:06Speaker 1: problem that how can a distributor or a manufacturer know
- 12:10Speaker 1: when a prescription is ultimately legitimate or not. So it
- 12:14Speaker 1: is a highly complex problem. Richard, I want to give
- 12:16Speaker 1: you the last word. We only have about thirty seconds.
- 12:18Speaker 1: But but but I want to want to let you
- 12:20Speaker 1: be clear were you was that your position on the
- 12:22Speaker 1: on the what the manufacturers could do, or you just
- 12:25Speaker 1: sort of laying out what the plaintiff's case was there.
- 12:28Speaker 1: I was laying out the plaintiff's case. I think Jody
- 12:31Speaker 1: is of course right that the manufacturers are perhaps somewhat
- 12:34Speaker 1: belatedly responding to this and uh uh in a number
- 12:38Speaker 1: of ways, and uh hopefully that will will bear fruit. Unfortunately,
- 12:44Speaker 1: they were now faced with a crisis and it's going
- 12:48Speaker 1: to take a lot of time and effort to to
- 12:52Speaker 1: do something about it. I want to thank our guests,
- 12:55Speaker 1: Jody Abragan, partner at cad Walder, former d e A official,
- 12:59Speaker 1: and Richard Austin as a professor at the University of
- 13:01Speaker 1: Kentucky School of Law.